Cagrilintide + Semaglutide dosage chart

10 mg Blend

Cagrilintide is dosed at 250 mcg–2.4 mg weekly by subcutaneous injection in educational protocols, starting low and titrating upward. A 10 mg blend reconstituted with bacteriostatic water yields about 3.33 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total (1.67 mg/mL each peptide).
Typical weekly range: 0.25–2.4 mg of each peptide once weekly (gradual titration over 16+ weeks).
Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg each peptide on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days; avoid freeze–thaw cycles.
Injection frequency: Once weekly — same day each week.
Dosing schedule: 1 injection per week, 7 days apart. Hold titration steps for the listed number of weeks before increasing.

Standard / Gradual Titration (3 mL = ~3.33 mg/mL total)

WEEK/PHASE	DOSE PER PEPTIDE (MCG / MG)	UNITS (ML)
Weeks 1–4	250 mcg (0.25 mg) each	15 units (0.15 mL)
Weeks 5–8	500 mcg (0.50 mg) each	30 units (0.30 mL)
Weeks 9–12	1000 mcg (1.0 mg) each	60 units (0.60 mL)
Weeks 13–16	1700 mcg (1.7 mg) each	102 units (1.02 mL)
Week 17+	2400 mcg (2.4 mg) each	144 units (1.44 mL)

Reconstitution steps

1Draw 3.0 mL bacteriostatic water with a sterile syringe.
2Inject slowly down the vial wall; avoid foaming.
3Gently swirl/roll until fully dissolved (do not shake).
4Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 30 days.

Dosing Cycle & Timing

This compound follows a once-weekly schedule, not the 5 days on / 2 days off cycle used for daily peptides.

Frequency: once weekly — one injection every 7 days.
Pick a fixed dosing day (for example every Sunday) and keep it consistent week to week.
If a dose day is missed, administer within 48 hours; otherwise skip it and resume the normal day.
Do not split the weekly amount into daily doses — GLP-1 compounds have a long half-life.
Stay at each titration step for the full number of weeks shown in the schedule table before stepping up.

Protocol Overview

Concise summary of the once‑weekly regimen.

Goal: Support significant weight reduction through dual amylin + GLP‑1 receptor agonism.
Schedule: Weekly subcutaneous injections for 16+ weeks (maintenance thereafter).
Dose Range: 0.25–2.4 mg each peptide weekly with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; use within 30 days.

Dosing Protocol

Suggested weekly titration approach.

Start: 0.25 mg each weekly for 4 weeks.
Escalate: Increase stepwise every 4 weeks (0.5 → 1.0 → 1.7 → 2.4 mg each).
Target: 2.4 mg each weekly by Week 17+.
Frequency: Once per week (subcutaneous), same day each week.
Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document weekly dose and site rotation to maintain consistency.
Higher doses may increase GI side effects (nausea, reduced appetite); titrate gradually.

How This Works

Cagrilintide is a long‑acting amylin analog that reduces appetite via central satiety pathways, while Semaglutide activates GLP‑1 receptors to enhance glucose‑dependent insulin secretion and suppress glucagon. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP‑1 enhances pancreatic β‑cell function and central appetite suppression. Clinical trials of the co‑administered regimen (CagriSema) show greater body‑weight reduction than either agent alone.

Potential Benefits & Side Effects

Observations from clinical literature.

Weight reduction: Phase 2 trials report mean body‑weight loss of ~15–17% at 32 weeks with the combination, exceeding Semaglutide monotherapy.
Glycemic control: In type 2 diabetes, HbA1c reductions were observed alongside weight loss.
GI tolerability: Nausea, vomiting, and diarrhea are the most common adverse events; gradual titration minimizes severity.
Injection‑site reactions: Mild and transient in clinical reports.

Lifestyle Factors

Complementary strategies for best outcomes.

Pair with a balanced, protein‑forward diet tailored to energy needs.
Combine resistance training and aerobic activity to reinforce metabolic adaptations.
Prioritize sleep and stress management to support adherence and recovery.
Stay hydrated and eat slowly to reduce GI discomfort.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources.

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
For volumes exceeding 1 mL (e.g., 1.44 mL at maintenance dose), inject slowly over several seconds.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Supplies needed

Plan covers the full 17-week protocol at the lowest listed starting dose: 0.5 mg per dose, once weekly (17 administrations in total), using 10 mg vials. After mixing with 3 mL, the concentration is 3.33 mg/mL and each dose requires 0.15 mL total.

Cagrilintide + Semaglutide vials (10 mg Blend each)

Vials are rounded up only after calculating the whole protocol: ceil(8.5 ÷ 10) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.

Full protocol (17 weeks): 1 vial (8.5 mg needed ÷ 10 mg)

Insulin syringes (U-100, 1 mL)

One fresh syringe per administration.

Full protocol (17 weeks): 17 syringes

Bacteriostatic water (10 mL bottles)

Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).

Full protocol (17 weeks): 1 × 10 mL bottle

Alcohol swabs

One for the vial stopper per draw + one for each injection site (once weekly).

Full protocol (17 weeks): 34 swabs

Supply	Full protocol (17 weeks)
Cagrilintide + Semaglutide vials (10 mg Blend each)Vials are rounded up only after calculating the whole protocol: ceil(8.5 ÷ 10) = 1. Usable peptide remaining in an opened vial carries forward to the next dose.	1 vial (8.5 mg needed ÷ 10 mg)
Insulin syringes (U-100, 1 mL)One fresh syringe per administration.	17 syringes
Bacteriostatic water (10 mL bottles)Use 3 mL per vial for reconstitution (1 × 3 mL = 3 mL).	1 × 10 mL bottle
Alcohol swabsOne for the vial stopper per draw + one for each injection site (once weekly).	34 swabs

Cagrilintide + Semaglutide dosage FAQs

How much bacteriostatic water do you use to reconstitute Cagrilintide + Semaglutide?

Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total (1.67 mg/mL each peptide). for a 10 mg Blend vial. Add the water slowly against the inside wall of the vial and swirl — never shake — until the powder fully dissolves.

How often is Cagrilintide + Semaglutide administered in research protocols?

Injection frequency: Once weekly — same day each week.

What does the Cagrilintide + Semaglutide standard / gradual titration (3 ml = ~3.33 mg/ml total) look like?

Weeks 1–4 — 250 mcg (0.25 mg) each — 15 units (0.15 mL); Weeks 5–8 — 500 mcg (0.50 mg) each — 30 units (0.30 mL); Weeks 9–12 — 1000 mcg (1.0 mg) each — 60 units (0.60 mL); Weeks 13–16 — 1700 mcg (1.7 mg) each — 102 units (1.02 mL). The full table above lists every step with matching syringe units.

What are the mixing steps for Cagrilintide + Semaglutide?

Draw 3.0 mL bacteriostatic water with a sterile syringe. Inject slowly down the vial wall; avoid foaming. Gently swirl/roll until fully dissolved (do not shake).

How should reconstituted Cagrilintide + Semaglutide be stored?

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days; avoid freeze–thaw cycles..

How many insulin syringe units equal a Cagrilintide + Semaglutide dose?

Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.

Is Cagrilintide + Semaglutide approved for human use?

No. Cagrilintide + Semaglutide is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.

Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.

On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.